Name(s) Developer(s) Indication Mechanism of action Route of administration

Rimegepant (BHV-3000)

Biohaven Pharmaceutical Holding Co. Ltd., of New Haven, Conn.


CGRP antagonist

Oral and buccal

OMB-157 (ofatumumab sc)

Novartis AG, of Basel, Switzerland

Multiple sclerosis

Anti-CD20 (MAb)

Subcutaneous injection

Ozanimod (RPC-1063)

Celgene Corp., of Summit, N.J. (subsidiary of Bristol-Myers Squibb)

Multiple sclerosis

S1P1 and S1P5 receptor agonist



Akebia Therapeutics Inc., of Cambridge, Mass., Mitsubishi Tanabe Pharma America Inc., of Jersey City, N.J., Otsuka Pharmaceutical Co., of Tokyo

Anemia due to chronic kidney disease

HIF-PH inhibitor


Valrox (valoctocogene roxaparvovec; BMN-270)

Biomarin Pharmaceutical Inc., of San Rafael, Calif.

Hemophilia A

FVIII gene therapy (via AAV5 vector)

Intravenous infusion

Filgotinib (GLPG-0634)

Gilead Sciences Inc., of Foster City, Calif., NV, of Mechelen, Belgium

Rheumatoid arthritis

JAK1 selective inhibitor


Rybelsus (semaglutide, oral, once daily)

Novo Nordisk A/S, of Bagsvaerd, Denmar

Type 2 diabetes mellitus

Long-acting GLP-1 analog


Inclisiran (ALN-PCSsc; ALN-60212; PCSK9si)

The Medicines Co., of Parsippany, N.J. (subsidiary of Novartis)


PCSK9 small interference RNA (siRNA)

Subcutaneous injection

Sacituzumab govitecan (IMMU-132)

Immunomedics Inc., of Morris Plains, N.J., Medicine Inc., of New York

Metastatic triple-negative breast cancer


Intravenous infusion

Enhertu (trastuzumab deruxtecan; DS-8201a)

Daiichi Sankyo Co. Ltd., of Tokyo, Astrazeneca plc, Cambridge, U.K.

Unresectable or metastatic HER2-positive breast cancer

Anti-HER2-exatecan ADC

Intravenous infusion

Liso-cel (JCAR-017; lisocabtagene maraleucel)

Celgene, of Summit, N.J. (subsidiary of Bristol-Myers Squibb Co., of Princeton, N.J.)

Large B-cell lymphoma

Anti-CD19 CAR T-cell therapy

Intravenous infusion


Source: Cortellis and BioWorld.

No Comments